Meridian Medica — Valerian

01

Identity

Botanical Profile

Valeriana officinalis L. — Root and rhizome. Native to Europe and parts of Asia; naturalized in North America. Widely cultivated in England, Germany, Netherlands, and the United States for medicinal use.

Root: Strong, distinctive musky-earthy odor that intensifies with drying (due to isovaleric acid formation). Taste: bitter, warm, slightly sweet with a persistent unpleasant aftertaste. The smell is polarizing — some find it deeply offensive. Fresh root is milder than dried.

Species Integrity

Valeriana officinalis is a species complex with significant chemical variation. European pharmacopoeias require minimum 0.17% valerenic acid and 0.3% sesquiterpenic acids for quality compliance.

02

Compounds

Active Compound Profile

Valerenic acid and derivatives

0.3–0.8% of dried root

Positive allosteric modulator of GABA-A receptors (binds beta-3 subunit); inhibits GABA transaminase, increasing synaptic GABA levels; anxiolytic and sedative mechanism

Valepotriates (valtrate, isovaltrate, didrovaltrate)

0.5–2.0% (highly variable; unstable — degrade during drying and storage)

Cytotoxic and sedative in vitro; likely decompose to baldrinals in GI tract; may contribute to sedative effect but mechanism debated

Isovaleric acid

Formed during drying from valepotriate degradation

GABA-A receptor partial agonist; contributes to the characteristic odor; mild sedative activity

Flavonoids (linarin, hesperidin)

Variable; minor constituents

Adenosine receptor interaction; mild sedative and anxiolytic activity; synergistic with valerenic acid

Absorption

Standardized extract for valerenic acid: Valerenic acid is the primary identified active; standardized extracts ensure consistent GABA-A modulation from dose to dose

03

Pathways

Mechanism of Action

★★★☆☆ GABA-A Receptor Modulation Valerenic acid is a positive allosteric modulator of GABA-A receptors at the beta-3 subunit, enhancing GABAergic inhibitory neurotransmission without directly binding the benzodiazepine site

★★★☆☆ GABA Transaminase Inhibition Valerenic acid and aqueous extract components inhibit GABA transaminase, the enzyme that breaks down synaptic GABA, effectively increasing GABA availability in the brain

★★★☆☆ Adenosine A1 Receptor Interaction Linarin and other flavonoid constituents interact with adenosine A1 receptors, contributing to sedative and sleep-promoting effects

★★★☆☆ HPA Axis Regulation / Cortisol Modulation GABAergic enhancement reduces hypothalamic CRH release, decreasing ACTH and cortisol output; anxiolytic effect reduces stress-driven HPA axis activation

★★★☆☆ Serotonin Receptor Interaction Valerian extract shows partial agonist activity at 5-HT5a receptors; may influence serotonergic regulation of sleep-wake cycles

04

Biomarkers

What It Moves in Your Labs

Biomarker	Direction	Target	Mechanism
Cortisol rhythm (salivary 4-point)	Normalize	High morning, low evening pattern restored	GABAergic HPA axis calming reduces evening cortisol elevation; supports natural diurnal cortisol rhythm
Sleep quality (PSQI score)	Improve	PSQI <5 (good sleep quality)	GABA-A modulation + adenosine receptor interaction reduce sleep latency and improve sleep architecture
TSH	Optimize	1.0–2.0 mIU/L	Improved sleep quality supports circadian TSH secretion; TSH peaks during early sleep — disrupted sleep blunts this peak
hs-CRP	Decrease	<1.0 mg/L	Improved sleep reduces inflammatory cytokine production; sleep deprivation independently elevates CRP and IL-6

05

Extraction

Extraction & Preparation

Standardized extract (0.8% valerenic acid): Concentrated valerenic acid; variable valepotriate and volatile retention

Solubility · Moderately lipophilic; soluble in ethanol; poorly water-solubleMenstruum · 60% ethanol (dried root) or 70% ethanol (fresh root)Plant material · Dried or fresh valerian root and rhizome, choppedMaceration time · 4–6 weeks (agitate daily)Ratio · 1:5 (dried) or 1:2 (fresh)

07

Dosing

Dosing Framework

Evening dose: 30–60 minutes before desired sleep time. Consistent nightly dosing is more effective than occasional use.

Dose 1

Sleep: 300–600mg standardized extract, 30–60 min before bed

Take consistently for 2–4 weeks for full effect; single-night use is less effective than cumulative use

Dose 2

Anxiety: 200–300mg extract, 2–3x daily

Lower daytime doses provide anxiolytic effect without significant sedation

Dose 3

Tincture (sleep): 3–5 mL evening dose

Take in warm water or tea; the Evening Calm Blend provides multi-herb synergy

08

Synergies

Synergy Partners

★★★☆☆ Lemon Balm (Melissa officinalis) Lemon balm inhibits GABA transaminase (different GABA mechanism than valerian's receptor modulation); rosmarinic acid adds calming effect; combination is well-studied with superior outcomes vs either alone

★★★☆☆ Passionflower (Passiflora incarnata) Passionflower contains chrysin (GABA-A benzodiazepine site modulator); different binding site than valerenic acid; additive GABAergic anxiolysis

★★★☆☆ Skullcap (Scutellaria lateriflora) Baicalin and other flavonoids modulate GABA-A receptors; complementary nervine relaxant; traditional combination in Western herbalism

★★★☆☆ Magnesium (glycinate or threonate) Magnesium is a natural NMDA receptor antagonist and GABA modulator; potentiates valerian's GABAergic effects; addresses common magnesium deficiency in Hashimoto's

★★★☆☆ Ashwagandha (Withania somnifera) Ashwagandha modulates cortisol and HPA axis from the adaptogenic side; valerian calms via GABAergic mechanism — complementary HPA axis support from different angles

Signature Stack

THE EVENING RESET
Components: Valerian (root) + Lemon Balm (leaf) + Passionflower (herb) + Skullcap (herb) + Magnesium Glycinate · Multi-pathway convergence: GABA-A positive allosteric modulation (valerenic acid) + GABA transaminase inhibition (lemon balm) + benzodiazepine site modulation (passionflower chrysin) + GABA-A flavonoid modulation (skullcap) + NMDA antagonism (magnesium) · The Evening Reset targets the GABA system from five different angles simultaneously, creating comprehensive inhibitory neurotransmission support for sleep and anxiety without any single pathway being overstimulated. This is the pharmacological sophistication of multi-herb formulation. · Practical integration: Evening Calm Tincture Blend 30–60 min before bed + magnesium glycinate 200–400mg. Consistent nightly practice for 2–4 weeks builds cumulative benefit.

09

Safety

Contraindications & Interactions

Minor Sedative medication interaction Additive CNS depression with benzodiazepines, barbiturates, zolpidem, alcohol, and other sedatives. GABA-A modulation potentiates these drugs.

Minor Anesthesia interaction Valerian may potentiate anesthetic agents and prolong post-anesthesia sedation. Case reports of prolonged recovery.

Minor Paradoxical stimulation (~10% of users) A subset of individuals experience increased anxiety, restlessness, or insomnia with valerian. Mechanism unclear; may relate to individual GABA receptor subunit expression.

Avoid Pregnancy / Lactation Insufficient safety data in pregnancy. Some animal studies suggest possible reproductive toxicity at very high doses. Traditional use suggests reasonable safety at moderate doses.

Minor Hepatotoxicity (very rare, debated) Rare case reports of liver injury associated with valerian, though causality is difficult to establish (often involved multi-ingredient products). Valepotriates are hepatotoxic in vitro but likely decompose before absorption.

11

Evidence

Evidence Base

★★★☆☆ Sleep Quality Improvement Moderate — Meta-analysis positive; effect size modest but consistent

★★★☆☆ Anxiety Reduction Moderate — Positive RCTs; comparable to low-dose diazepam in one study

★★☆☆☆ Benzodiazepine Tapering Support Emerging — Positive case series; limited controlled data

★★☆☆☆ Menstrual Pain Relief Emerging — Single positive RCT; mechanistic plausibility

★★☆☆☆ HPA Axis / Cortisol Regulation Emerging — Strong mechanistic rationale; limited direct cortisol measurement data

Evidence Gaps

The highest-value research gap for Meridian Medica: no published RCT has evaluated valerian specifically for sleep and HPA axis outcomes in Hashimoto's patients. Hashimoto's patients have high rates of insomnia, anxiety, and cortisol dysrhythmia — all targets for valerian's GABAergic mechanism. A crossover study measuring sleep quality (PSQI), salivary cortisol rhythm, and thyroid function markers in Hashimoto's women receiving valerian extract vs placebo would be directly informative.

Quality Alert

Valerian adulteration concerns are moderate:

12

Protocol

Protocol Integration

Layer 1: Hypothalamic / Autonomic — HPA axis, circadian rhythm, stress response

Layer 2: Systemic Nutritional Repletion — Micronutrient optimization, antioxidant defense

Layer 3: Gut Permeability / Microbiome — Tight junction repair, motility, SIBO management

Recipe Integration

Evening Calm Tincture Blend (signature preparation)

3–5 mL, 30–60 min before bed

Feed the Markers

Valerian appears in the following Meridian Medica protocol contexts: